GH Stock Analysis: Buy, Sell, or Hold?
GH - Guardant Health, Inc. Common Stock
$157.21
-2.33 (-1.46%)
âŧ
5d:
-6.69%
30d:
+1.43%
90d:
+59.35%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 7, 2026 at $168.48 · last confirmed Aug 11, 2026
Strength: 7.5/10
Get Alerted When GH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GH is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GH is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: GH is currently trading at $157.21, which is considered fair relative to its 30-day fair value range of $150.32 to $164.52.
Technical Outlook: Technically, GH is in a strong uptrend. The price is currently testing key support at $155.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GH scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $194.29 (+23.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GH is in a strong uptrend. The price is currently testing key support at $155.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GH scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $194.29 (+23.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$150.32 -
$164.52
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
Protect Your Profits
Holding GH? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.6% below Wall St target ($194.29)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$150.32 -
$164.52
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$155.05
Resistance Level
$171.92
Current Trend
Strong Uptrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-349.28
Wall Street Target
$194.29
(+23.6%)
Revenue Growth (YoY)
44.3%
Profit Margin
-38.3%
Share & Embed Analysis
Last updated: August 16, 2026 2:37 AM ET
Data refreshes hourly during market hours. Next update: 3:37 AM
Data refreshes hourly during market hours. Next update: 3:37 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Musa Tariq
SELL
116 shares
2026-04-16
Terilyn J Monroe
SELL
3832 shares
2026-04-06
Musa Tariq
SELL
348 shares
2026-03-18
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
31 analysts |
$631 | 45 HOLD |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$228 | 46 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$292 | 38 SELL |
|
IQV
IQVIA Holdings Inc |
BUY
23 analysts |
$275 | 45 HOLD |
Advanced GH Option Strategies
Professional options setups generated by AI based on today's GH price and gamma walls.
